Clarity Pharmaceuticals (ASX:CU6) signed a copper-64 isotope supply agreement with the University of Queensland's Australian Institute for Biotechnology and Nanotechnology, according to a Wednesday Australian bourse filing.
The supply agreement will support the firm's clinical trials with copper-64 SAR-bisPSMA imaging agent in Australia for prostate cancer patients. It will also support the rollout of two theranostic preclinical programs, SAR-bisFAP and SAR-trastuzumab.
It will expand the manufacturing capability of the agent for the phase three CLARIFY and AMPLIFY registrational trials in Australia, an ongoing investigator-initiated trial, as well as the Co-PSMA and SECuRE theranostic trials.
The firm's shares rose 2% in recent trading on Wednesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。